Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab - Genentech/Roche

Next Previous
Search
Drug Profile

Pertuzumab - Genentech/Roche

Alternative Names: Anti-2C4 monoclonal antibody; Omnitarg; Perjeta; R-1273; RG-1273; rhuMab-2C4; rhuMAb2C4; Ro 436-8451/F01; RO-4368451-F01; RO4368451

Latest Information Update: 14 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; Roche
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Japan Breast Cancer Research Group; Medica Scientia Innovation Research; Roche; West German Study Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Ovarian cancer
  • Phase II Brain metastases; Colorectal cancer
  • Phase I HER2 positive breast cancer
  • Discontinued Gastric cancer; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 15 Jan 2025 The West German Study Group, in collaboration with Roche completes a phase-II clinical trial in Breast cancer (Combination therapy, Neoadjuvant therapy) in Germany (IV) (NCT01817452)
  • 28 Nov 2024 Roche completes phase III APHINITY trial in Breast cancer (Adjuvant therapy, Combination therapy, Early-stage disease) at multiple countries worldwide (NCT01358877)
  • 13 Sep 2024 Efficacy data from the phase II trial in Breast cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top